This is supported by results in SLE patients treated with rituximab, where normalization of CD1d expression on newly repopulated CD19+CD24hiCD38hi B cells corresponded to normalization of the invariant natural killer T (iNKT) cell number and function, as well as improved clinical response (57). Here, CD19 is linked to systemic lupus erythematosus.